Literature DB >> 9864190

Glucose stimulates phagocytosis of unopsonized Pseudomonas aeruginosa by cultivated human alveolar macrophages.

S Y Wong1, L M Guerdoud, A Cantin, D P Speert.   

Abstract

Glucose has previously been shown to increase the in vitro phagocytosis of unopsonized Pseudomonas aeruginosa by freshly explanted murine peritoneal macrophages (PM) and cultivated alveolar macrophages (AM). This study examined the effect of glucose on the same phagocytosis process in human AM in order to determine whether this phenomenon is conserved among species. Freshly explanted human AM phagocytosed unopsonized P. aeruginosa at a low level (2 bacteria/macrophage/30 min), whereas mouse AM ingested a negligible number of P. aeruginosa (0.01 bacterium/macrophage/30 min). Glucose had no effect on this or other phagocytic processes in freshly explanted mouse or human AM. However, following in vitro cultivation for 72 h, human AM phagocytosed three to four times more unopsonized P. aeruginosa than did freshly explanted cells, but only in the presence of glucose. This glucose-inducible phagocytic response had also been observed in cultivated murine AM. Although similar increases were also detected for the phagocytosis of latex particles and complement-coated sheep erythrocytes by cultivated human AM, these processes were not glucose dependent. The lack of response to glucose in freshly explanted mouse AM was attributed to insufficient glucose transport; however, freshly explanted human AM exhibited significant facilitative glucose transport activity that was inhibitable by cytochalasin B and phloretin. Taken together, these results suggest that the process of glucose-inducible phagocytosis of unopsonized P. aeruginosa is conserved among macrophages from different species, including humans, and that AM, but not PM, required cultivation for this glucose effect to occur. Glucose transport by AM appears to be necessary but not sufficient for phagocytosis of unopsonized P. aeruginosa.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9864190      PMCID: PMC96271     

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  23 in total

1.  Bronchoalveolar lavage in the normal volunteer subject. I. Technical aspects and intersubject variability.

Authors:  D B Ettensohn; M J Jankowski; P G Duncan; P A Lalor
Journal:  Chest       Date:  1988-08       Impact factor: 9.410

2.  Substrate transport by the pulmonary alveolar macrophage. Effects of smoke components.

Authors:  R B Low; C A Bulman
Journal:  Am Rev Respir Dis       Date:  1977-09

3.  Biochemical analyses of bronchoalveolar lavage fluids of healthy human volunteer smokers and nonsmokers.

Authors:  R B Low; G S Davis; M S Giancola
Journal:  Am Rev Respir Dis       Date:  1978-11

4.  Comparative oxidative microbicidal activity of human blood monocytes and alveolar macrophages and activation by recombinant gamma interferon.

Authors:  B Kemmerich; T H Rossing; J E Pennington
Journal:  Am Rev Respir Dis       Date:  1987-08

5.  Glucose, K+, and albumin concentrations in the alveolar milieu of normal humans and pulmonary sarcoidosis patients.

Authors:  D Valeyre; P Soler; G Basset; P Loiseau; J Pre; P Turbie; J P Battesti; R Georges
Journal:  Am Rev Respir Dis       Date:  1991-05

6.  Lung antibacterial defense mechanisms in infant and adult rats: implications for the pathogenesis of group B streptococcal infections in the neonatal lung.

Authors:  T R Martin; C E Rubens; C B Wilson
Journal:  J Infect Dis       Date:  1988-01       Impact factor: 5.226

7.  Metabolism of glucose, glutamine, long-chain fatty acids and ketone bodies by murine macrophages.

Authors:  P Newsholme; R Curi; S Gordon; E A Newsholme
Journal:  Biochem J       Date:  1986-10-01       Impact factor: 3.857

8.  Pulmonary alveolar macrophage. Defender against bacterial infection of the lung.

Authors:  E Goldstein; W Lippert; D Warshauer
Journal:  J Clin Invest       Date:  1974-09       Impact factor: 14.808

9.  Role of mutant CFTR in hypersusceptibility of cystic fibrosis patients to lung infections.

Authors:  G B Pier; M Grout; T S Zaidi; J C Olsen; L G Johnson; J R Yankaskas; J B Goldberg
Journal:  Science       Date:  1996-01-05       Impact factor: 47.728

10.  The effects of cortisone therapy on lung macrophage host defense function and glucose metabolism.

Authors:  P W Gudewicz
Journal:  Circ Shock       Date:  1981
View more
  5 in total

1.  Glucose in bronchial aspirates increases the risk of respiratory MRSA in intubated patients.

Authors:  B J Philips; J Redman; A Brennan; D Wood; R Holliman; D Baines; E H Baker
Journal:  Thorax       Date:  2005-09       Impact factor: 9.139

2.  Myeloid Slc2a1-Deficient Murine Model Revealed Macrophage Activation and Metabolic Phenotype Are Fueled by GLUT1.

Authors:  Alex J Freemerman; Liyang Zhao; Ajeeth K Pingili; Bin Teng; Alyssa J Cozzo; Ashley M Fuller; Amy R Johnson; J Justin Milner; Maili F Lim; Joseph A Galanko; Melinda A Beck; James E Bear; Jeremy D Rotty; Lavanya Bezavada; Heather S Smallwood; Michelle A Puchowicz; Juan Liu; Jason W Locasale; Douglas P Lee; Brian J Bennett; E Dale Abel; Jeff C Rathmell; Liza Makowski
Journal:  J Immunol       Date:  2019-01-18       Impact factor: 5.422

3.  Role of pulmonary alveolar macrophages in defense of the lung against Pseudomonas aeruginosa.

Authors:  D O Cheung; K Halsey; D P Speert
Journal:  Infect Immun       Date:  2000-08       Impact factor: 3.441

4.  Glucose controls morphodynamics of LPS-stimulated macrophages.

Authors:  Gerda Venter; Frank T J J Oerlemans; Mietske Wijers; Marieke Willemse; Jack A M Fransen; Bé Wieringa
Journal:  PLoS One       Date:  2014-05-05       Impact factor: 3.240

Review 5.  Phagocytosis-Inflammation Crosstalk in Sepsis: New Avenues for Therapeutic Intervention.

Authors:  Marcela Hortová-Kohoutková; Federico Tidu; Marco De Zuani; Vladimír Šrámek; Martin Helán; Jan Frič
Journal:  Shock       Date:  2020-11       Impact factor: 3.533

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.